CXCL12 promotes spinal nerve regeneration and functional recovery after spinal cord injury

Li, Jingyuan; Wu, Yiling; Chen, Ping; Huang, Xiaoxia; Liu, Yongli; Peng, Minjing; Wu, Rongqian

doi:10.1097/wnr.0000000000001613

Cited by 12 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 341 , 342 Existing data support that SDF-1 acts as the guiding signal for the regeneration of axon growth in damaged neurons and enhances spinal nerve regeneration. 343 , 344 Hence, the ability of BM-MSCs to express SDF-1 in response to the neuronal environment provides a unique neuronal protective effect that could explain the potential therapeutic efficacy of BM-MSCs in the treatment of neurodegenerative diseases (Fig. 3b ).…”

Section: Proposed Mechanism Of Bm-mscs In the Treatment Of Acquired B...mentioning

confidence: 99%

Stem cell-based therapy for human diseases

Hoang

Pham

Bach

et al. 2022

Sig Transduct Target Ther

484

138

View full text Add to dashboard Cite

Recent advancements in stem cell technology open a new door for patients suffering from diseases and disorders that have yet to be treated. Stem cell-based therapy, including human pluripotent stem cells (hPSCs) and multipotent mesenchymal stem cells (MSCs), has recently emerged as a key player in regenerative medicine. hPSCs are defined as self-renewable cell types conferring the ability to differentiate into various cellular phenotypes of the human body, including three germ layers. MSCs are multipotent progenitor cells possessing self-renewal ability (limited in vitro) and differentiation potential into mesenchymal lineages, according to the International Society for Cell and Gene Therapy (ISCT). This review provides an update on recent clinical applications using either hPSCs or MSCs derived from bone marrow (BM), adipose tissue (AT), or the umbilical cord (UC) for the treatment of human diseases, including neurological disorders, pulmonary dysfunctions, metabolic/endocrine-related diseases, reproductive disorders, skin burns, and cardiovascular conditions. Moreover, we discuss our own clinical trial experiences on targeted therapies using MSCs in a clinical setting, and we propose and discuss the MSC tissue origin concept and how MSC origin may contribute to the role of MSCs in downstream applications, with the ultimate objective of facilitating translational research in regenerative medicine into clinical applications. The mechanisms discussed here support the proposed hypothesis that BM-MSCs are potentially good candidates for brain and spinal cord injury treatment, AT-MSCs are potentially good candidates for reproductive disorder treatment and skin regeneration, and UC-MSCs are potentially good candidates for pulmonary disease and acute respiratory distress syndrome treatment.

show abstract

Section: Proposed Mechanism Of Bm-mscs In the Treatment Of Acquired B...mentioning

confidence: 99%

Stem cell-based therapy for human diseases

Hoang

Pham

Bach

et al. 2022

Sig Transduct Target Ther

484

138

View full text Add to dashboard Cite

show abstract

“…The present study is the first report showing that Cxcl12 might contribute to the recovery of erectile nerve function after CN injury. Li et al [27] reported that Cxcl12 (SDF-1a) promoted neural functional recovery by inducing the formation of neuronal connections and suppressing glial scar in a rat spinal cord model. Yang et al [28] reported that the Cxcl12 signalling pathway may function as a bridge between injury and repair in a rat optical nerve injury model.…”

Section: Discussionmentioning

confidence: 99%

“…Li et al. [27] reported that Cxcl12 (SDF‐1α) promoted neural functional recovery by inducing the formation of neuronal connections and suppressing glial scar in a rat spinal cord model. Yang et al.…”

Section: Discussionmentioning

confidence: 99%

Intravenously engrafted human multilineage‐differentiating stress‐enduring (Muse) cells rescue erectile function after rat cavernous nerve injury

Koyama,

Yamashita,

Kato

et al. 2023

BJU International

View full text Add to dashboard Cite

ObjectiveTo evaluate the effect of intravenous administration of human multilineage‐differentiating stress‐enduring (Muse) cells on rat postoperative erectile dysfunction (ED) with cavernous nerve (CN) injury without an immunosuppressant.Materials and MethodsMale Sprague–Dawley rats were randomised into three groups after CN crush injury. Either human‐Muse cells, non‐Muse mesenchymal stem cells (MSCs) (both 1.0 × 105 cells), or vehicle was infused intravenously at 3 h after CN injury without immunosuppressant. Erectile function was assessed by measuring intracavernous pressure (ICP) and arterial pressure (AP) during pelvic nerve electrostimulation 28 days after surgery. At 48 h and 28 days after intravenous infusion of Muse cells, the homing of Muse cells and non‐Muse MSCs was evaluated in the major pelvic ganglion (MPG) after CN injury. In addition, expressions of C‐X‐C motif chemokine ligand (Cxcl12) and glial cell line‐derived neurotrophic factor (Gdnf) in the MPG were examined by real‐time polymerase chain reaction. Statistical analyses and comparisons among groups were performed using one‐way analysis of variance followed by the Tukey test for parametric data and Kruskal–Wallis test followed by the Dunn–Bonferroni test for non‐parametric data.ResultsThe mean (SEM) ICP/AP values at 28 days were 0.51 (0.02) in the Muse cell group, 0.37 (0.03) in the non‐Muse MSC group, and 0.36 (0.04) in the vehicle group, showing a significant positive response in the Muse cell group compared with the non‐Muse and vehicle groups (P = 0.013 and P = 0.010, respectively). In the MPG, Muse cells were observed to be engrafted at 48 h and expressed Schwann cell markers S100 (~46%) and glial fibrillary acidic protein (~24%) at 28 days, while non‐Muse MSCs were basically not engrafted at 48 h. Higher gene expression of Cxcl12 (P = 0.048) and Gdnf (P = 0.040) was found in the MPG of the Muse group than in the vehicle group 48 h after infusion.ConclusionIntravenously engrafted human Muse cells recovered rat erectile function after CN injury in a rat model possibly by upregulating Cxcl12 and Gdnf.

show abstract

“…SDF-1 activates the PI3K/AKT pathway and leads to mTOR activation ( Dillenburg-Pilla et al, 2015 ). SDF-1 causes potent axon growth in vivo after both optic nerve crush and SCI ( Jaerve et al, 2011 , 2012a ; Heskamp et al, 2013 ; Negro et al, 2017 ; Stewart et al, 2017 ; Li et al, 2021 ). Jaerve et al (2011) used SDF-1 to examine how aging differentially affects the potential for sprouting and regeneration within the spinal cord after injury ( Jaerve et al, 2011 ).…”

Section: Aging In Animal Modelsmentioning

confidence: 99%

Improving translatability of spinal cord injury research by including age as a demographic variable

Stewart

Jones

Gensel

2022

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Pre-clinical and clinical spinal cord injury (SCI) studies differ in study design, particularly in the demographic characteristics of the chosen population. In clinical study design, criteria such as such as motor scores, neurological level, and severity of injury are often key determinants for participant inclusion. Further, demographic variables in clinical trials often include individuals from a wide age range and typically include both sexes, albeit historically most cases of SCI occur in males. In contrast, pre-clinical SCI models predominately utilize young adult rodents and typically use only females. While it is often not feasible to power SCI clinical trials to test multi-variable designs such as contrasting different ages, recent pre-clinical findings in SCI animal models have emphasized the importance of considering age as a biological variable prior to human experiments. Emerging pre-clinical data have identified case examples of treatments that diverge in efficacy across different demographic variables and have elucidated several age-dependent effects in SCI. The extent to which these differing or diverging treatment responses manifest clinically can not only complicate statistical findings and trial interpretations but also may be predictive of worse outcomes in select clinical populations. This review highlights recent literature including age as a biological variable in pre-clinical studies and articulates the results with respect to implications for clinical trials. Based on emerging unpredictable treatment outcomes in older rodents, we argue for the importance of including age as a biological variable in pre-clinical animal models prior to clinical testing. We believe that careful analyses of how age interacts with SCI treatments and pathophysiology will help guide clinical trial design and may improve both the safety and outcomes of such important efforts.

show abstract

CXCL12 promotes spinal nerve regeneration and functional recovery after spinal cord injury

Cited by 12 publications

References 26 publications

Stem cell-based therapy for human diseases

Stem cell-based therapy for human diseases

Intravenously engrafted human multilineage‐differentiating stress‐enduring (Muse) cells rescue erectile function after rat cavernous nerve injury

Improving translatability of spinal cord injury research by including age as a demographic variable

Contact Info

Product

Resources

About